DREAMLAND for Acute Myeloid Leukemia

N/A

Waitlist Available

Led By Areej El-Jawahri, MD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is comparing two mobile apps for patients with acute myeloid leukemia. One app, DREAMLAND, provides psychological support to help reduce anxiety and depression. The other app, CERENA, offers tips on staying physically healthy. The goal is to see which app better improves the patients' quality of life.

Eligible Conditions

Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Anxiety Symptoms

Depression Symptoms

Post-Traumatic Stress Disorder (PTSD) Symptoms

+2 more

Other study objectives

Coping

Health care utilization

Self-efficacy

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: DREAMLANDExperimental Treatment1 Intervention

Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA. * Participants will use DREAMLAND and during hospitalization for treatment of AML to learn how to cope most effectively with the diagnosis of AML using an iPad provided by the study team or participant's own iPad. * Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days.

Group II: CERENAActive Control1 Intervention

Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA. * Participants will use the mobile app CERENA during hospitalization for treatment of AML to learn how to best care for themselves using an iPad provided by the study team or participant's own iPad. * Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days.

Do I qualify?Apply below to find out